Seelos Therapeutics to Participate in the 10th Annual LifeSci Partners Corporate Access Event

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced participation in the 10th Annual LifeSci Partners Corporate Access Event from January 6-8 and 11-14, 2021.

Rhea-AI Summary

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced participation in the 10th Annual LifeSci Partners Corporate Access Event from January 6-8 and 11-14, 2021. Chairman and CEO Raj Mehra, Ph.D. will hold one-on-one meetings via conference calls. The company focuses on developing therapies for central nervous system disorders and rare diseases, working on late-stage clinical assets targeting serious conditions like Acute Suicidal Ideation, amyotrophic lateral sclerosis, and more. For further details, visit Seelos Therapeutics.

Argus Session date unavailable

+4.36% session move Open Argus

Details

News Market Reaction – SEEL

The recorded move for SEEL in the trading session of this news was +4.36%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Dec. 8, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 10^th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 meetings via conference calls.

For additional information about the 10^th Annual LifeSci Partners Corporate Access Event: https://www.lifesciadvisors.com/

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos 

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-10th-annual-lifesci-partners-corporate-access-event-301187641.html

SOURCE Seelos Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Seelos Therapeutics participating in on January 6-8 and 11-14, 2021?

Seelos Therapeutics is participating in the 10th Annual LifeSci Partners Corporate Access Event.

Who is hosting the meetings for Seelos Therapeutics at the event?

Raj Mehra, Ph.D., Chairman and CEO, will host one-on-one meetings via conference calls.

What is the focus of Seelos Therapeutics?

Seelos Therapeutics focuses on developing therapies for central nervous system disorders and rare diseases.

What are some conditions Seelos Therapeutics is targeting?

The company targets conditions including Acute Suicidal Ideation, amyotrophic lateral sclerosis, and other CNS and rare diseases.

Where can I find more information about Seelos Therapeutics?

More information can be found on their website at http://seelostherapeutics.com.